As a result, CNS indications such as brain disease in systemic lupus erythematosus (SLE) or multiple sclerosis where both macrophage and B cell biologies are implicated in disease pathogenesis may be alternative options for BTK inhibition. The gene discussed is BTK; the disease is brain disorder.